Claims for Patent: 6,207,661

Summary for Patent: 6,207,661

Title:	Premixed formulation of piperacillin sodium and tazobactam sodium injection
Abstract:	The present invention provides a premixed form of a buffered piperacillin product having a near neutral pH and capable of a shelf life of at least nine months, with freezer storage (-20.degree. C. or lower), or a refrigerated shelf life of up to 14 days at about 5.degree. C. The piperacillin may additionally contain a tazobactam component to inactivate beta-lactamases that commonly cause resistance to penicillins, allowing the piperacillin component to destroy susceptible bacteria. With the addition of dextrose, the premixed composition is physiologically isosmotic.
Inventor(s):	Thompson; Stacey S. (Wheeling, IL), Chilamkurti; Rao (Gurnee, IL), Samuel; Mary (Lindenhurst, IL), Stephens; Norma (Skokie, IL)
Assignee:	Baxter International Inc. (Deerfield, IL)
Application Number:	09/255,513
Patent Claims:	1. A pharmaceutical composition suitable for administration parenterally, comprising a buffered solution having an effective amount of piperacillin and a pH adjusted to be in the range of from about 6.1 to about 6.9. 2. The pharmaceutical composition of claim 1 wherein the effective amount of piperacillin is provided in the form of piperacillin sodium, and wherein the concentration of piperacillin is within the range of from about 20 to about 80 mg/ml of solution. 3. The pharmaceutical composition of claim 2 wherein the concentration of piperacillin within the range of about 30 to about 70 mg/ml of solution. 4. The pharmaceutical composition of claim 2 wherein the concentration of piperacillin is within the range of about 38 to about 62 mg/ml of solution. 5. The pharmaceutical composition of claim 1 wherein the pH is adjusted to about 6.5. 6. The pharmaceutical composition of claim 1 further comprising a buffer. 7. The pharmaceutical composition of claim 6 wherein the buffer is a citrate. 8. The pharmaceutical composition of claim 7 wherein the buffer is sodium citrate. 9. The pharmaceutical composition of claim 8 wherein the concentration of the sodium citrate buffer is within the range of from about 1 to about 4 mg/ml of solution. 10. The pharmaceutical composition of claim 9 wherein the concentration of the sodium citrate buffer is within the range of from about 1.5 to about 3.5 mg/ml of solution. 11. The pharmaceutical composition of claim 9 wherein the concentration of the sodium citrate buffer is within the range of from about 1.8 to about 3.2 mg/ml of solution. 12. The pharmaceutical composition of claim 1 further comprising an effective amount of tazobactam. 13. The pharmaceutical composition of claim 12 wherein the effective amount of tazobactam is provided in the form of tazobactam sodium, and wherein the concentration of tazobactam is within the range of from about 0.0 to about 9.0 mg/ml of solution. 14. The pharmaceutical composition of claim 13 wherein the concentration of tazobactam is within the range of from about 4 to about 8 mg/ml of solution. 15. The pharmaceutical composition of claim 13 wherein the concentration of tazobactam is within the range of from about 4.8 to about 7.8 mg/ml of solution. 16. The pharmaceutical composition of claim 12 wherein the pH is adjusted to about 6.5. 17. The pharmaceutical composition of claim 16 further comprising a buffer. 18. The pharmaceutical composition of claim 17 wherein the buffer is a citrate. 19. The pharmaceutical composition of claim 18 wherein the buffer is sodium citrate. 20. The pharmaceutical composition of claim 19 wherein the concentration of the sodium citrate buffer is within the range of from about 1 to about 4 mg/ml of solution. 21. The pharmaceutical composition of claim 20 wherein the concentration of the sodium citrate buffer is within the range of from about 1.5 to about 3.5 mg/ml of solution. 22. The pharmaceutical composition of claim 20 wherein the concentration of the sodium citrate buffer is within the range of from about 1.8 to about 3.2 mg/ml of solution. 23. The pharmaceutical composition of claim 1 further comprising an effective amount of dextrose to render the composition physiologically isosmotic. 24. The pharmaceutical composition of claim 23 wherein the concentration of dextrose is within the range of from about 5 to about 30 mg/ml of solution. 25. The pharmaceutical composition of claim 24 wherein the concentration of dextrose is preferably within the range of from about 6 to about 22 mg/ml of solution. 26. A process of making a pharmaceutical piperacillin composition having a refrigerated shelf life in excess of 7 days, comprising the steps of: a. dissolving an effective amount of piperacillin into a suitable liquid forming a premixed solution; b. adjusting the pH of the premixed solution to a range of from about 6.1 to about 6.9; c. filling suitable containers with the premixed solution; and d. storing the containers of premixed solution in a suitable atmosphere at about 5.degree. C. .+-.3.degree. C. 27. The process of claim 26 further comprising the step of dissolving an effective amount of tazobactam into the premixed solution. 28. The process of claim 26 further comprising the step of buffering the solution. 29. The process of claim 26 wherein the suitable atmosphere is -20.degree. C. or lower. 30. The process of claim 26 further comprising the step of adding an amount of dextrose to the premixed solution to make the composition physiologically isosmotic. 31. The process of claim 26 wherein the effective amount of piperacillin is provided by piperacillin sodium at a concentration within the range of from about 20 to about 80 mg/ml of suitable liquid. 32. The process of claim 31 wherein the concentration of the piperacillin is within the range of from about 30 to about 70 mg/ml of suitable liquid. 33. The process of claim 31 wherein the concentration of the piperacillin is within the range of from about 38 to about 62 mg/ml of suitable liquid. 34. The process of claim 27 wherein the effective amount of tazobactam is provided by tazobactam sodium at a concentration within the range of from about 0.0 to about 9.0 mg/ml of suitable liquid. 35. The process of claim 34 wherein the concentration of the tazobactam is within the range of from about 4 to about 8 mg/ml of suitable liquid. 36. The process of claim 34 wherein the concentration of the tazobactam is within the range of from about 4.8 to about 7.8 mg/ml of suitable liquid. 37. The process of claim 27 further comprising the step of buffering the solution. 38. The process of claim 37 wherein the step of buffering the premixed solution includes the step of adding an effective amount of a citrate to the premixed solution. 39. The process of claim 38 where the citrate includes sodium citrate and is within the range of from about 1 to about 4 mg/ml of suitable liquid. 40. The process of claim 38 where the citrate includes sodium citrate and is within the range of from about 1.5 to about 3.5 mg/ml of suitable liquid. 41. The process of claim 38 where the citrate includes sodium citrate and is within the range of from about 1.8 to about 3.2 mg/ml of suitable liquid. 42. The process of claim 26 wherein the pH of the premixed solution is about 6.5.